{"pmid":32360480,"pmcid":"PMC7189851","title":"Candidate drugs against SARS-CoV-2 and COVID-19.","text":["Candidate drugs against SARS-CoV-2 and COVID-19.","Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may prevent spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.","Pharmacol Res","McKee, Dwight L","Sternberg, Ariane","Stange, Ulrike","Laufer, Stefan","Naujokat, Cord","32360480"],"abstract":["Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may prevent spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic."],"journal":"Pharmacol Res","authors":["McKee, Dwight L","Sternberg, Ariane","Stange, Ulrike","Laufer, Stefan","Naujokat, Cord"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360480","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.phrs.2020.104859","keywords":["covid-19","sars-cov-2","arbidol","camostat","chloroquine","drugs","favipiravir","lopinavir","phytochemicals","remdesivir","ritonavir"],"e_drugs":["remdesivir","Hydroxychloroquine","Chloroquine","Lopinavir","Serine","Ritonavir","favipiravir","arbidol"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495475777537,"score":9.490897,"similar":[{"pmid":32448818,"title":"Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.","text":["Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.","The number of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly increased, although the WHO declared a pandemic. However, drugs that function against SARS-CoV-2 have not been established. SARS-CoV-2 has been suggested to bind angiotensin-converting enzyme 2, the receptor of the SARS coronavirus. SARS coronavirus and coronavirus 229E, the cause of the common cold, replicate through cell-surface and endosomal pathways using a protease, the type II transmembrane protease. To examine the effects of protease inhibitors on the replication of coronavirus 229E, we pretreated primary cultures of human nasal epithelial (HNE) cells with camostat or nafamostat, each of which has been used for the treatment of pancreatitis and/or disseminated intravascular coagulation. HNE cells were then infected with coronavirus 229E, and viral titers in the airway surface liquid of the cells were examined. Pretreatment with camostat (0.1-10 mug/mL) or nafamostat (0.01-1 mug/mL) reduced the titers of coronavirus 229E. Furthermore, a significant amount of type II transmembrane protease protein was detected in the airway surface liquid of HNE cells. Additionally, interferons have been reported to have antiviral effects against SARS coronavirus. The additive effects of interferons on the inhibitory effects of other candidate drugs to treat SARS-CoV-2 infection, such as lopinavir, ritonavir and favipiravir, have also been studied. These findings suggest that protease inhibitors of this type may inhibit coronavirus 229E replication in human airway epithelial cells at clinical concentrations. Protease inhibitors, interferons or the combination of these drugs may become candidate drugs to inhibit the replication of SARS-CoV-2.","Tohoku J Exp Med","Yamaya, Mutsuo","Nishimura, Hidekazu","Deng, Xue","Kikuchi, Akiko","Nagatomi, Ryoichi","32448818"],"abstract":["The number of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly increased, although the WHO declared a pandemic. However, drugs that function against SARS-CoV-2 have not been established. SARS-CoV-2 has been suggested to bind angiotensin-converting enzyme 2, the receptor of the SARS coronavirus. SARS coronavirus and coronavirus 229E, the cause of the common cold, replicate through cell-surface and endosomal pathways using a protease, the type II transmembrane protease. To examine the effects of protease inhibitors on the replication of coronavirus 229E, we pretreated primary cultures of human nasal epithelial (HNE) cells with camostat or nafamostat, each of which has been used for the treatment of pancreatitis and/or disseminated intravascular coagulation. HNE cells were then infected with coronavirus 229E, and viral titers in the airway surface liquid of the cells were examined. Pretreatment with camostat (0.1-10 mug/mL) or nafamostat (0.01-1 mug/mL) reduced the titers of coronavirus 229E. Furthermore, a significant amount of type II transmembrane protease protein was detected in the airway surface liquid of HNE cells. Additionally, interferons have been reported to have antiviral effects against SARS coronavirus. The additive effects of interferons on the inhibitory effects of other candidate drugs to treat SARS-CoV-2 infection, such as lopinavir, ritonavir and favipiravir, have also been studied. These findings suggest that protease inhibitors of this type may inhibit coronavirus 229E replication in human airway epithelial cells at clinical concentrations. Protease inhibitors, interferons or the combination of these drugs may become candidate drugs to inhibit the replication of SARS-CoV-2."],"journal":"Tohoku J Exp Med","authors":["Yamaya, Mutsuo","Nishimura, Hidekazu","Deng, Xue","Kikuchi, Akiko","Nagatomi, Ryoichi"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448818","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1620/tjem.251.27","keywords":["sars-cov-2","camostat","coronavirus 229e","nafamostat","type ii transmembrane protease"],"e_drugs":["Ritonavir","camostat","favipiravir","nafamostat","Lopinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213991714818,"score":472.75546},{"pmid":32470470,"pmcid":"PMC7255230","title":"Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.","text":["Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.","The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2118 on-going clinical trials underway, but to date none of these drugs have consistently proven effective. Cathepsin L (CatL) is an endosomal cysteine protease. It mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells, virus and host cell endosome membrane fusion, and viral RNA release for next round of replication. Here we summarize data regarding seven CatL-selective inhibitors that block coronavirus entry into cultured host cells and provide a mechanism to block SARS-CoV-2 infection in humans. Given the rapid growth of the SARS-CoV-2-positive population worldwide, ready-to-use CatL inhibitors should be explored as a treatment option. We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system.","Pharmacol Ther","Liu, Tianxiao","Luo, Songyuan","Libby, Peter","Shi, Guo-Ping","32470470"],"abstract":["The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2118 on-going clinical trials underway, but to date none of these drugs have consistently proven effective. Cathepsin L (CatL) is an endosomal cysteine protease. It mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells, virus and host cell endosome membrane fusion, and viral RNA release for next round of replication. Here we summarize data regarding seven CatL-selective inhibitors that block coronavirus entry into cultured host cells and provide a mechanism to block SARS-CoV-2 infection in humans. Given the rapid growth of the SARS-CoV-2-positive population worldwide, ready-to-use CatL inhibitors should be explored as a treatment option. We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system."],"journal":"Pharmacol Ther","authors":["Liu, Tianxiao","Luo, Songyuan","Libby, Peter","Shi, Guo-Ping"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470470","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.pharmthera.2020.107587","keywords":["covid-19","camostat mesylate","cathepsin l","chloroquine","protease inhibitor cocktail","sars-cov-2"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["arbidol","Serine","Chloroquine","Hydroxychloroquine","lopinavir-ritonavir drug combination","remdesivir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887241555968,"score":393.10886},{"pmid":32395418,"pmcid":"PMC7211915","title":"An Update on Current Therapeutic Drugs Treating COVID-19.","text":["An Update on Current Therapeutic Drugs Treating COVID-19.","The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2.","Curr Pharmacol Rep","Wu, Renyi","Wang, Lujing","Kuo, Hsiao-Chen Dina","Shannar, Ahmad","Peter, Rebecca","Chou, Pochung Jordan","Li, Shanyi","Hudlikar, Rasika","Liu, Xia","Liu, Zhigang","Poiani, George J","Amorosa, Louis","Brunetti, Luigi","Kong, Ah-Ng","32395418"],"abstract":["The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2."],"journal":"Curr Pharmacol Rep","authors":["Wu, Renyi","Wang, Lujing","Kuo, Hsiao-Chen Dina","Shannar, Ahmad","Peter, Rebecca","Chou, Pochung Jordan","Li, Shanyi","Hudlikar, Rasika","Liu, Xia","Liu, Zhigang","Poiani, George J","Amorosa, Louis","Brunetti, Luigi","Kong, Ah-Ng"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395418","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s40495-020-00216-7","keywords":["anakinra","azithromycin","covid-19","chloroquine","convalescent plasma","epoprostenol","favipiravir","hydroxychloroquine","lopinavir","methylprednisolone","nitric oxide","oseltamivir","remdesivir","sar-cov-2","sarilumab","sirolimus","tocilizumab","traditional chinese medicine","umifenovir","vitamin c"],"locations":["Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666627827806502913,"score":392.53525},{"pmid":32394467,"title":"A global treatments for coronaviruses including COVID-19.","text":["A global treatments for coronaviruses including COVID-19.","In late December 2019 in Wuhan, China, several patients with viral pneumonia were identified as 2019 novel coronavirus (2019-nCoV). So far, there are no specific treatments for patients with coronavirus disease-19 (COVID-19), and the treatments available today are based on previous experience with similar viruses such as severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Influenza virus. In this article, we have tried to reach a therapeutic window of drugs available to patients with COVID-19. Cathepsin L is required for entry of the 2019-nCoV virus into the cell as target teicoplanin inhibits virus replication. Angiotensin-converting-enzyme 2 (ACE2) in soluble form as a recombinant protein can prevent the spread of coronavirus by restricting binding and entry. In patients with COVID-19, hydroxychloroquine decreases the inflammatory response and cytokine storm, but overdose causes toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and zanamivir are invalid for 2019-nCoV and are not recommended for treatment but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the progression of MERS-CoV disease and can be useful for patients of COVID-19 and, in combination with Arbidol, has a direct antiviral effect on early replication of SARS-CoV. Ribavirin reduces hemoglobin concentrations in respiratory patients, and remdesivir improves respiratory symptoms. Use of ribavirin in combination with LPV/r in patients with SARS-CoV reduces acute respiratory distress syndrome and mortality, which has a significant protective effect with the addition of corticosteroids. Favipiravir increases clinical recovery and reduces respiratory problems and has a stronger antiviral effect than LPV/r. currently, appropriate treatment for patients with COVID-19 is an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids.","J Cell Physiol","Yousefi, Bahman","Valizadeh, Saeid","Ghaffari, Hadi","Vahedi, Azadeh","Karbalaei, Mohsen","Eslami, Majid","32394467"],"abstract":["In late December 2019 in Wuhan, China, several patients with viral pneumonia were identified as 2019 novel coronavirus (2019-nCoV). So far, there are no specific treatments for patients with coronavirus disease-19 (COVID-19), and the treatments available today are based on previous experience with similar viruses such as severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Influenza virus. In this article, we have tried to reach a therapeutic window of drugs available to patients with COVID-19. Cathepsin L is required for entry of the 2019-nCoV virus into the cell as target teicoplanin inhibits virus replication. Angiotensin-converting-enzyme 2 (ACE2) in soluble form as a recombinant protein can prevent the spread of coronavirus by restricting binding and entry. In patients with COVID-19, hydroxychloroquine decreases the inflammatory response and cytokine storm, but overdose causes toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and zanamivir are invalid for 2019-nCoV and are not recommended for treatment but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the progression of MERS-CoV disease and can be useful for patients of COVID-19 and, in combination with Arbidol, has a direct antiviral effect on early replication of SARS-CoV. Ribavirin reduces hemoglobin concentrations in respiratory patients, and remdesivir improves respiratory symptoms. Use of ribavirin in combination with LPV/r in patients with SARS-CoV reduces acute respiratory distress syndrome and mortality, which has a significant protective effect with the addition of corticosteroids. Favipiravir increases clinical recovery and reduces respiratory problems and has a stronger antiviral effect than LPV/r. currently, appropriate treatment for patients with COVID-19 is an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids."],"journal":"J Cell Physiol","authors":["Yousefi, Bahman","Valizadeh, Saeid","Ghaffari, Hadi","Vahedi, Azadeh","Karbalaei, Mohsen","Eslami, Majid"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394467","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/jcp.29785","keywords":["covid-19","antiviral","coronavirus","drug","treatment"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ribavirin","lopinavir-ritonavir drug combination","arbidol","Zanamivir","Oseltamivir","Teicoplanin","Hydroxychloroquine","peramivir","favipiravir","remdesivir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627827776094208,"score":390.9771},{"pmid":32142651,"pmcid":"PMC7102627","title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","text":["SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.","Cell","Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan","32142651"],"abstract":["The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention."],"journal":"Cell","authors":["Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32142651","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.cell.2020.02.052","keywords":["ace2","covid-19","sars-cov-2","tmprss2","coronavirus","entry","neutralization","priming","spike"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Serine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490692173825,"score":366.9591}]}